2. Academic Validation
  3. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models

Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models

  • Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00710-19. doi: 10.1128/AAC.00710-19.
Hoan N Le # 1,  Vuvi G Tran # 1,  Trang T T Vu 1,  Emmanuelle Gras 1 2,  Vien T M Le 1,  Marcos Gabriel Pinheiro 1 3,  Fábio Aguiar-Alves 1 3,  Erika Schneider-Smith 1,  Henry Clay Carter 1,  Bret R Sellman 4,  C Kendall Stover 4,  Antonio DiGiandomenico 5,  Binh An Diep 6
Affiliations

Affiliations

  • 1 Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
  • 2 François Rabelais University, Tours, France.
  • 3 Pathology Program, Fluminense Federal University, Rio de Janeiro, Brazil.
  • 4 Microbial Sciences, AstraZeneca, Gaithersburg, Maryland, USA.
  • 5 Microbial Sciences, AstraZeneca, Gaithersburg, Maryland, USA [email protected] [email protected].
  • 6 Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA [email protected] [email protected].
  • # Contributed equally.
PMID: 31160288 DOI: 10.1128/AAC.00710-19
Abstract

Pseudomonas aeruginosa is a challenge for clinicians due to increasing drug resistance and dwindling treatment options. We report on the activity of MEDI3902, an antibody targeting type 3 secretion protein PcrV and Psl exopolysaccharide, in rabbit bloodstream and lung Infection models. MEDI3902 prophylaxis or treatment was protective in both acute models and exhibited enhanced activity when combined with a subtherapeutic dose of meropenem. These findings further support MEDI3902 for the prevention or treatment of serious P. aeruginosa infections.

Keywords

Pseudomonas aeruginosa; bloodstream infections; immunotherapy; pneumonia.

Figures
Products